TABLE 3

Correlation of insulin resistance to CAC volume; OR of any CAC at 6-year visit associated with insulin resistance by GIR and by failure of NEFA suppression in clamp stage 2

ModelSpearman correlation coefficient: glucose infusion rate vs. CAC volume for total clamp cohort (n = 87)
6-year visit CAC volumeBaseline to 6-year visit change in CAC3-year to 6-year visit change in CAC
1: Adjusted for age
    GIR (mg/kg FFM/min)−0.42 (P < 0.0001)−0.41 (P < 0.0001)−0.24 (P = 0.028)
    Stage 2 NEFA level (μM)0.41 (P < 0.0001)0.40 (P = 0.0001)0.27 (P = 0.01)
2: Adjusted for age, sex, diabetes status
    GIR (mg/kg FFM/min)−0.31 (P = 0.005)−0.30 (P = 0.006)−0.19 (P = 0.08)
    Stage 2 NEFA level (μM)0.32 (P = 0.003)0.30 (P = 0.005)0.24 (P = 0.03)
3: Adjusted for age: type 1 diabetic group alone
    GIR (mg/kg FFM/min)−0.28 (P = 0.08)−0.28 (P = 0.09)NS
    Stage 2 NEFA level (μM)0.31 (P = 0.06)0.28 (P = 0.08)NS
4: Adjusted for age: nondiabetic group alone
    GIR (mg/kg FFM/min)−0.39 (P = 0.006)−0.41 (P = 0.004)NS
    Stage 2 NEFA level (μM)0.39 (P = 0.007)0.39 (P = 0.008)NS
Logistic regression analysis: odds ratio for any CAC at 6-year visit with increase in insulin resistance (n = 87)
Mean ± SDOR per 1 SD change (95% CI) (P)
GIR (mg/kg FFM/min)9.8 ± 6.10.45 (0.22–0.93) (0.03)
Stage 2 NEFA (μM)268 ± 1862.40 (1.08–5.32) (0.032)